Arkansas Children's provides right-sized care for your child. U.S. News & World Report has ranked Arkansas Children's in seven specialties for 2022-2023.
Sign up online to quickly and easily manage your child's medical information and connect with us whenever you need.
We're focused on improving child health through exceptional patient care, groundbreaking research, continuing education, and outreach and prevention.
Our ERs are staffed 24/7 with doctors, nurses and staff who know kids best – all trained to deliver right-sized care for your child in a safe environment.
Arkansas Children's provides right-sized care for your child. U.S. News & World Report has ranked Arkansas Children's in seven specialties for 2022-2023.
Find health tips, patient stories, and news you can use to champion children.
Our flu resources and education information help parents and families provide effective care at home.
We are dedicated to caring for children, allowing us to uniquely shape the landscape of pediatric care in Arkansas.
Our researchers are driven by their limitless curiosity to discover new and better ways to make these children better today and healthier tomorrow.
We're focused on improving child health through exceptional patient care, groundbreaking research, continuing education, and outreach and prevention.
Then we're looking for you! Work at a place where you can change lives...including your own.
When you give to Arkansas Children's, you help deliver on our promise of a better today and a healthier tomorrow for the children of Arkansas and beyond
The gift of time is one of the most precious gifts you can give. You can make a difference in the life of a sick child.
Support and participate in this advocacy effort on behalf of Arkansas’ youth and our organization.
Difluoromethylornithine (DFMO) will be used in an open label, single agent, multicenter, study for patients with neuroblastoma in remission. In this study subjects will receive 730 Days by mouth difluoromethylornithine (DFMO) at a dose of 500 to 1000 mg/m2 twice daily on each day of study. This study will focus on the use of DFMO in high risk neuroblastoma patients that are in remission as a strategy to prevent recurrence.
This study evaluates the use of carfilzomib in combination with cyclophosphamide and etoposide for children with relapsed/refractory solid tumors or leukemia.
A Phase I/II, Multicenter, Open-Label, Multi-Arm Study Evaluating the Safety, Tolerability in Combination with Either Chemotherapy or Venetoclax in the Treatment of Pediatric and Young Adult Patients with Relapsed/Refractory Acute Leukemias or Solid Tumors
Treatment of cHL in children and young adults – evaluation of pembrolizumab in a subgroup with inadequate early response to frontline chemotherapy.
This study will evaluate the use of Difluoromethylornithine (DFMO) as a single agent in patients with high risk medulloblastoma after completing therapy as maintenance therapy with the hopes of preventing relapse.
The purpose of this study is to test the effectiveness of using an investigational agent called DFMO along with etoposide for Neuroblastoma.
A Phase 2b Trial of the MEK 1/2 Inhibitor (MEK) PD-0325901 in Adult and Pediatric Patients with Neurofibromatosis Type 1 (NF1)-Associated Inoperable Plexiform Neurofibromas (PNs) that are Causing Significant Morbidity
This is an open-label, sequential-arm, Phase 1b/2 clinical trial of bempegaldesleukin in combination with nivolumab in pediatric participants with malignancies that are refractory, relapsed, or participants for whom curative treatments are lacking.
A prospective open label, multicenter study to evaluate the feasibility and side effects of using molecularly guided therapy in combination with standard therapy followed by a Randomized Controlled Trial of standard immunotherapy with or without DFMO followed by DFMO maintenance for Subjects with Newly Diagnosed High-Risk Neuroblastoma.